Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ansbert Gadicke Sells 54,452 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 54,452 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $1.21, for a total value of $65,886.92. Following the completion of the transaction, the insider directly owned 5,904,720 shares of the company’s stock, valued at approximately $7,144,711.20. The trade was a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Wednesday, November 5th, Ansbert Gadicke sold 47,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total value of $58,499.00.
• On Tuesday, November 4th, Ansbert Gadicke sold 140,488 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total value of $171,395.36.
• On Monday, November 3rd, Ansbert Gadicke sold 94,063 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total value of $121,341.27.
• On Friday, October 31st, Ansbert Gadicke sold 114,044 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.28, for a total value of $145,976.32.
• On Thursday, October 30th, Ansbert Gadicke sold 86,936 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.43, for a total value of $124,318.48.
• On Wednesday, October 29th, Ansbert Gadicke sold 134,240 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total value of $208,072.00.
• On Tuesday, October 28th, Ansbert Gadicke sold 69,068 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.64, for a total value of $113,271.52.
• On Monday, October 27th, Ansbert Gadicke sold 72,709 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.72, for a total value of $125,059.48.

Werewolf Therapeutics Stock Down 1.6%

NASDAQ:HOWL traded down $0.02 during mid-day trading on Thursday, hitting $1.20. 647,728 shares of the company’s stock traded hands, compared to its average volume of 891,846. The company has a fifty day moving average of $1.61 and a 200 day moving average of $1.32. Werewolf Therapeutics, Inc. has a twelve month low of $0.60 and a twelve month high of $2.41. The company has a market capitalization of $58.25 million, a P/E ratio of -0.74 and a beta of 0.72. The company has a debt-to-equity ratio of 0.73, a quick ratio of 5.30 and a current ratio of 3.87.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. On average, analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds have recently modified their holdings of HOWL. Jane Street Group LLC purchased a new stake in shares of Werewolf Therapeutics in the second quarter worth about $409,000. Marshall Wace LLP purchased a new stake in shares of Werewolf Therapeutics in the second quarter worth about $113,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Werewolf Therapeutics in the second quarter worth about $92,000. AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics in the first quarter worth about $79,000. Finally, Nuveen LLC purchased a new stake in shares of Werewolf Therapeutics in the first quarter worth about $71,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Analyst Ratings Changes

HOWL has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. JMP Securities cut their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. Citigroup reissued a “buy” rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. Finally, Bank of America cut their price objective on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.